image
Healthcare - Biotechnology - NASDAQ - GB
$ 0.85865
-2.43 %
$ 704
Market Cap
-0.06
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BDRX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.859 USD, Biodexa Pharmaceuticals Plc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BDRX stock under the base case scenario is HIDDEN Compared to the current market price of 0.859 USD, Biodexa Pharmaceuticals Plc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BDRX stock under the best case scenario is HIDDEN Compared to the current market price of 0.859 USD, Biodexa Pharmaceuticals Plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BDRX

image
$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.520252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25Jul '25Jul '25
FINANCIALS
381 K REVENUE
-45.49%
-8.01 M OPERATING INCOME
10.28%
-5.73 M NET INCOME
19.07%
-12.3 M OPERATING CASH FLOW
-79.62%
-598 K INVESTING CASH FLOW
-125.66%
8.56 M FINANCING CASH FLOW
-16.32%
0 REVENUE
0.00%
-4.22 M OPERATING INCOME
-12.02%
-2.42 M NET INCOME
26.81%
-7.45 M OPERATING CASH FLOW
-55.07%
156 K INVESTING CASH FLOW
120.69%
3.91 M FINANCING CASH FLOW
-15.78%
Balance Sheet Biodexa Pharmaceuticals Plc
image
Current Assets 8.81 M
Cash & Short-Term Investments 1.67 M
Receivables 715 K
Other Current Assets 6.43 M
Non-Current Assets 5.97 M
Long-Term Investments 0
PP&E 324 K
Other Non-Current Assets 5.65 M
11.29 %4.84 %43.48 %38.20 %Total Assets$14.8m
Current Liabilities 5.03 M
Accounts Payable 707 K
Short-Term Debt 609 K
Other Current Liabilities 3.72 M
Non-Current Liabilities 1.42 M
Long-Term Debt 118 K
Other Non-Current Liabilities 1.31 M
10.95 %9.43 %57.57 %20.22 %Total Liabilities$6.5m
EFFICIENCY
Earnings Waterfall Biodexa Pharmaceuticals Plc
image
Revenue 381 K
Cost Of Revenue 4.07 M
Gross Profit -3.69 M
Operating Expenses 4.33 M
Operating Income -8.01 M
Other Expenses -2.28 M
Net Income -5.73 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)381k(4m)(4m)(4m)(8m)2m(6m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biodexa Pharmaceuticals Plc
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -5.73 M
Depreciation & Amortization 254 K
Capital Expenditures -774 K
Stock-Based Compensation 283 K
Change in Working Capital -3.74 M
Others -844 K
Free Cash Flow -13 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biodexa Pharmaceuticals Plc
image
BDRX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Biodexa Pharmaceuticals Plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune system attacks and destroys the beta cells that produce insulin. accessnewswire.com - 2 weeks ago
Result of General Meeting June 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces, announces that at its General Meeting held earlier today, all four resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting and General Meeting can be found in the Notice of the General Meeting on the Company's website at: https://biodexapharma.com/investors/corporate-governance/#agms. globenewswire.com - 3 weeks ago
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes (“T1D”). The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. globenewswire.com - 1 month ago
Shareholder Update May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update for shareholders. Financial position As of May 29, 2025, the Company had access to the following cash resources:     $ millions Cash at bank   5.7 Cash in escrow for eRapa Phase 3 program   4.4     10.1       Undrawn CPRIT grant for eRapa Phase 3 program   11.9       Debt   0.5 The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded. globenewswire.com - 1 month ago
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting May 22, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today. The Board of Directors is proposing four resolutions: Ordinary Resolutions       1. globenewswire.com - 1 month ago
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced its collaboration partner, Rapamycin Holdings, Inc. d/b/a Emtora Biosciences (“Emtora”) has been awarded an additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas (“CPRIT”). This award brings the total grant awarded by CPRIT to support the registrational Phase 3 program of eRapa in familial adenomatous polyposis (“FAP”) to $20.0 million. globenewswire.com - 1 month ago
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 1 month ago
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 study targeted at an addressable market of $7.3Bn Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the European Commission (EC) has granted Orphan Drug Designation for eRapa in familial adenomatous polyposis (FAP), a largely inherited precancerous disease of the colon for which there is currently no pharmaceutical intervention. ” This Orphan Drug Designation is another important step as we move our FAP program forward into a registrational Phase 3 study. globenewswire.com - 1 month ago
Result of General Meeting May 2, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that at its General Meeting held at 1.00pm BST today, ordinary resolutions 1 and 2 were passed by majorities of 62% and 61%, respectively. Special resolution 3 failed to pass with a majority vote of 71%. globenewswire.com - 2 months ago
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2 months ago
Notice of General Meeting April 17, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 2 May 2025 at 13:00 BST was posted to shareholders yesterday. The Board of Directors is proposing three resolutions: Ordinary Resolutions1. globenewswire.com - 2 months ago
Preliminary Results for the Year Ended 31 December 2024 April 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces its audited preliminary results for the year ended 31 December 2024. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 2048 0180 www.biodexapharma.com About Biodexa Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. globenewswire.com - 2 months ago
8. Profile Summary

Biodexa Pharmaceuticals Plc BDRX

image
COUNTRY GB
INDUSTRY Biotechnology
MARKET CAP $ 704
Dividend Yield 0.00%
Description Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Contact 1 Caspian Point, Cardiff, CF10 4DQ https://www.biodexapharma.com
IPO Date Dec. 7, 2015
Employees 13
Officers Mr. Stephen Anthony Stamp Chief Executive Officer, Chief Financial Officer, Company Secretary & Director Mr. Steve Ellul Chief Business Officer Dr. Gary A. Shangold CPI, FACOG, M.D. Chief Medical Officer Ms. Fiona Sharp Group Financial Controller Dr. Daniel Palmer MBA, Ph.D. Vice President of Technology